Zymeworks (NYSE:ZYME) Insider Sells $216,725.20 in Stock

Zymeworks Inc. (NYSE:ZYME) insider Paul Andrew Moore sold 9,560 shares of Zymeworks stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $22.67, for a total transaction of $216,725.20. Following the sale, the insider directly owned 48,497 shares in the company, valued at $1,099,426.99. The trade was a 16.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Paul Andrew Moore also recently made the following trade(s):

• On Monday, January 5th, Paul Andrew Moore sold 20,110 shares of Zymeworks stock. The stock was sold at an average price of $25.10, for a total value of $504,761.00.

Zymeworks Stock Performance

Shares of NYSE ZYME traded down $0.01 during mid-day trading on Monday, hitting $23.16. 1,062,235 shares of the stock traded hands, compared to its average volume of 1,412,548. Zymeworks Inc. has a 52 week low of $9.03 and a 52 week high of $28.49. The company has a market cap of $1.73 billion, a price-to-earnings ratio of -15.44 and a beta of 1.30. The stock has a fifty day moving average price of $24.32 and a 200-day moving average price of $18.42.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company had revenue of $27.61 million during the quarter, compared to analysts’ expectations of $33.69 million. During the same period last year, the company posted ($0.39) EPS. Zymeworks’s revenue was up 72.6% on a year-over-year basis. As a group, sell-side analysts predict that Zymeworks Inc. will post -1.39 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. B. Riley reaffirmed a “buy” rating and set a $40.00 price objective (up previously from $30.00) on shares of Zymeworks in a research report on Friday, November 21st. Citigroup assumed coverage on shares of Zymeworks in a report on Wednesday, December 3rd. They issued an “outperform” rating for the company. HC Wainwright increased their price target on shares of Zymeworks from $26.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Wells Fargo & Company raised shares of Zymeworks from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $25.00 to $33.00 in a research report on Friday, December 12th. Finally, JMP Securities set a $32.00 price objective on Zymeworks in a research report on Wednesday, December 3rd. Eleven analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $32.82.

Institutional Trading of Zymeworks

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZYME. Optiver Holding B.V. purchased a new position in shares of Zymeworks in the third quarter worth $26,000. Quarry LP bought a new stake in Zymeworks in the 3rd quarter valued at $50,000. Tower Research Capital LLC TRC increased its holdings in Zymeworks by 29.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,947 shares of the company’s stock valued at $62,000 after acquiring an additional 1,131 shares during the last quarter. CWM LLC lifted its stake in Zymeworks by 272.8% in the 2nd quarter. CWM LLC now owns 8,570 shares of the company’s stock worth $108,000 after purchasing an additional 6,271 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Zymeworks by 157.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,307 shares of the company’s stock valued at $129,000 after purchasing an additional 6,307 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with a focus on the discovery, development and commercialization of multifunctional biotherapeutics. Founded in 2003, the company applies proprietary protein engineering platforms to create novel antibody and protein-based therapies targeting oncology and other serious diseases. Zymeworks is publicly traded on the New York Stock Exchange under the symbol ZYME.

The company’s core technology platforms include Azymetric®, which enables the design of bispecific antibodies capable of engaging two distinct targets simultaneously, and the EFECT™ platform for fine-tuning antibody-drug conjugate properties.